Nitazene Control Act of 2025
Sponsored By: Representative Vindman, Eugene Simon [D-VA-7]
Introduced
Summary
Permanently classifies nitazene opioids as Schedule I. The bill would amend the Controlled Substances Act to add 2-benzylbenzimidazole opioids, commonly called nitazenes, to Schedule I, name examples such as etonitazene, isotonitazene, and protonitazene, convert any nitazenes temporarily scheduled under section 201(h) into permanent Schedule I substances, and make clear that new research on these drugs still requires proper registration and scheduling compliance.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Stricter federal limits on nitazenes
The bill would add nitazenes to Schedule I under federal drug law. It would cover the whole class of 2-benzylbenzimidazole opioids and related isomers, esters, ethers, and salts. Examples include etonitazene, isotonitazene, metonitazene, and protonitazene. Any nitazene that is temporarily scheduled now would become permanently Schedule I at enactment. This would sharply limit legal making, selling, importing, and possessing these drugs, except as allowed for research.
Registration needed to study nitazenes
The bill would not allow new nitazene research to start without proper approvals. Researchers, labs, and universities would need DEA registrations and must follow Schedule I rules. This requirement would apply upon enactment.
Sponsors & CoSponsors
Sponsor
Vindman, Eugene Simon [D-VA-7]
VA • D
Cosponsors
Rep. Baumgartner, Michael [R-WA-5]
WA • R
Sponsored 9/16/2025
Rep. Harris, Andy [R-MD-1]
MD • R
Sponsored 10/24/2025
Rep. Fitzpatrick, Brian K. [R-PA-1]
PA • R
Sponsored 11/7/2025
Davis (NC)
NC • D
Sponsored 11/18/2025
Rep. McCormick, Richard [R-GA-7]
GA • R
Sponsored 11/19/2025
Rep. Goldman, Daniel S. [D-NY-10]
NY • D
Sponsored 11/19/2025
Rep. Taylor, David J. [R-OH-2]
OH • R
Sponsored 11/28/2025
Rep. Mackenzie, Ryan [R-PA-7]
PA • R
Sponsored 12/10/2025
Rep. Harrigan, Pat [R-NC-10]
NC • R
Sponsored 12/16/2025
Kelly (PA)
PA • R
Sponsored 12/16/2025
Rep. Ross, Deborah K. [D-NC-2]
NC • D
Sponsored 12/16/2025
Rep. Thompson, Glenn [R-PA-15]
PA • R
Sponsored 12/16/2025
Onder
MO • R
Sponsored 12/18/2025
Bresnahan
PA • R
Sponsored 12/18/2025
Rep. Lawler, Michael [R-NY-17]
NY • R
Sponsored 12/19/2025
Rep. Houlahan, Chrissy [D-PA-6]
PA • D
Sponsored 12/19/2025
Rep. Carey, Mike [R-OH-15]
OH • R
Sponsored 1/7/2026
Rep. Neguse, Joe [D-CO-2]
CO • D
Sponsored 1/7/2026
Rep. Gill, Brandon [R-TX-26]
TX • R
Sponsored 1/12/2026
Pfluger
TX • R
Sponsored 1/12/2026
Liccardo
CA • D
Sponsored 1/13/2026
Rep. Lee, Susie [D-NV-3]
NV • D
Sponsored 1/13/2026
Schmidt
KS • R
Sponsored 2/10/2026
Salazar
FL • R
Sponsored 2/13/2026
Rep. Baird, James R. [R-IN-4]
IN • R
Sponsored 2/20/2026
Rep. Suozzi, Thomas R. [D-NY-3]
NY • D
Sponsored 3/3/2026
Rep. Fine, Randy [R-FL-6]
FL • R
Sponsored 4/15/2026
Rep. Fry, Russell [R-SC-7]
SC • R
Sponsored 4/15/2026
Rep. Goodlander, Maggie [D-NH-2]
NH • D
Sponsored 4/22/2026
Van Epps
TN • R
Sponsored 5/11/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov